LONDON: Evgen Pharma announced that Helen Kuhlman PhD will be joining the Company as Chief Business Officer effective from 1 April 2021.
Dr Kuhlman has over 20 years’ experience in government funding and equity investment together with scientific and business roles in public and private R&D-based biotechnology companies. She joins Evgen from the Development Bank of Wales where she was responsible for equity investment in technology companies and for managing investments in the bank’s portfolio companies.
Prior to that Helen was Vice-President of Corporate Development at Chronos Therapeutics Ltd and was previously at Innovate UK where she created and delivered the £180m Biomedical Catalyst competitive grant scheme funded by the UK government. Dr Kuhlman holds a PhD in physiology and pharmacology from the University of Leicester, UK.
Dr Huw Jones CEO of Evgen commented: “We are delighted to appoint Helen to a key senior role within the Company as we increase our focus on potential partnering activities for SFX-01. Helen will also have a key role within the team in providing a commercial focus on our indication selection, horizon scanning and competitor intelligence activities.”
Evgen Pharma is a clinical stage drug development company developing sulforaphane based medicines for the treatment of multiple diseases. www.evgen.com